Issac Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Issac Jung has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Tran
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Brandon Tsai
Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA 90095, USA
13 shared publications - Changhyeon Hong
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - David Lee
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Erin Lim
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Furong Huang
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
13 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Neuroendocrine prostate cancer (NEPC) is an aggressive and therapy-resistant subtype of advanced prostate cancer characterized by poor prognosis and limited treatment options. Enzalutamide (Enz), an androgen receptor pathway inhibitor, is a standard second-line therapy for prostate adenocarcinoma. However, Enz resistance promotes not only neuroendocrine differentiation (NED) but also the induction of stemness-associated programs in prostate adenocarcinoma cells. We identified the de novo DNA methyltransferase DNMT3B as a stemness-related gene upregulated in Enz-resistant prostate adenocarcinoma cells and found that its expression is further significantly elevated in NEPC compared with prostate adenocarcinoma. Our studies reveal that DNMT3B is a critical driver of NEPC development by coordinating the regulation of neuroendocrine and stemness transcriptional networks. Genetic inhibition of DNMT3B suppresses NEPC cell proliferation by impairing cell-cycle progression and triggering apoptosis both in vitro and in vivo. DNMT3B loss altered NED-associated, stemness, and epithelial-associated genes. We further uncover a reciprocal regulatory relationship between DNMT3B and the neuroendocrine transcriptional repressor REST. Using a human prostate cell transformation model that recapitulates NEPC evolution, we demonstrate that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype. Finally, pharmacologic inhibition of DNMT3B with the selective inhibitor nanaomycin A reduces NEPC tumor growth and suppresses NED and stemness marker expression without apparent acute toxicity in vivo. Implications:DNMT3B drives therapy-induced lineage plasticity in prostate cancer, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Neuroendocrine prostate cancer (NEPC) is an aggressive and therapy-resistant subtype of advanced prostate cancer characterized by poor prognosis and limited treatment options. Enzalutamide (Enz), an androgen receptor pathway inhibitor, is a standard second-line therapy for prostate adenocarcinoma. However, Enz resistance promotes not only neuroendocrine differentiation (NED) but also the induction of stemness-associated programs in prostate adenocarcinoma cells. We identified the de novo DNA methyltransferase DNMT3B as a stemness-related gene upregulated in Enz-resistant prostate adenocarcinoma cells and found that its expression is further significantly elevated in NEPC compared with prostate adenocarcinoma. Our studies reveal that DNMT3B is a critical driver of NEPC development by coordinating the regulation of neuroendocrine and stemness transcriptional networks. Genetic inhibition of DNMT3B suppresses NEPC cell proliferation by impairing cell-cycle progression and triggering apoptosis both in vitro and in vivo. DNMT3B loss altered NED-associated, stemness, and epithelial-associated genes. We further uncover a reciprocal regulatory relationship between DNMT3B and the neuroendocrine transcriptional repressor REST. Using a human prostate cell transformation model that recapitulates NEPC evolution, we demonstrate that DNMT3B is required for both the initiation and maintenance of the NEPC phenotype. Finally, pharmacologic inhibition of DNMT3B with the selective inhibitor nanaomycin A reduces NEPC tumor growth and suppresses NED and stemness marker expression without apparent acute toxicity in vivo. Implications:DNMT3B drives therapy-induced lineage plasticity in prostate cancer, and its inhibition suppresses NEPC growth and differentiation, highlighting it as a promising therapeutic target for treatment-resistant disease.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S1. DNMT3B loss altered the cell cycle of NEPC cells and increased apoptosis in NEPC cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S1. DNMT3B loss altered the cell cycle of NEPC cells and increased apoptosis in NEPC cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S10. Nanaomycin A treatment suppresses the growth and neuroendocrine differentiation in MSKCC-EF1 xenografts.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S10. Nanaomycin A treatment suppresses the growth and neuroendocrine differentiation in MSKCC-EF1 xenografts.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S4. ChIP-seq datasets suggesting that the REST protein is enriched in the DNMT3B gene, especially the promoter region, in various human cancer cell lines and organoids.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S4. ChIP-seq datasets suggesting that the REST protein is enriched in the DNMT3B gene, especially the promoter region, in various human cancer cell lines and organoids.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S3. Quantification of neuroendocrine differentiation markers and NEPC-associated transcription factors.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S3. Quantification of neuroendocrine differentiation markers and NEPC-associated transcription factors.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S2. DNMT3B loss delayed the growth of NEPC xenografts.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S2. DNMT3B loss delayed the growth of NEPC xenografts.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S11. Global 5-methyl-2′-deoxycytidine level was not altered by DNMT3B loss or Nanaomycin A treatment.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S11. Global 5-methyl-2′-deoxycytidine level was not altered by DNMT3B loss or Nanaomycin A treatment.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S5. Prostate cell organoids transduced with PARCB and sgDNMT3B proliferate as PARCB + sgSCR.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S5. Prostate cell organoids transduced with PARCB and sgDNMT3B proliferate as PARCB + sgSCR.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S6. Genetic modulation of DNMT3B regulates NEPC tumor growth and differentiation.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S6. Genetic modulation of DNMT3B regulates NEPC tumor growth and differentiation.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S7. Nanaomycin A binds to and destabilizes DNMT3B.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from DNMT3B Drives Neuroendocrine Lineage Plasticity and Aggressive Progression in Prostate Cancer
Figure S7. Nanaomycin A binds to and destabilizes DNMT3B.